Novo Nordisk ends two more heart-drug trials as pipeline setbacks mount
Novo Nordisk has stopped two additional heart-drug trials, adding to setbacks in its development pipeline. The move puts more pressure on the company’s existing portfolio and upcoming clinical milestones to support its growth story.
The story
The company has pulled the plug on two more trials involving heart drugs, according to a September 17 report. The decision expands the list of discontinued development programs but leaves the specific drug candidates, trial phases and reasons for the stoppages unclear here.
Novo Nordisk enters the development setback with a large established business: FY2025 revenue was $309.1B, up 6.4% year over year, with an 81.0% gross margin and 33.1% net margin. Those figures describe the year ended December 31, 2025, rather than the current quarter.
The immediate connection is to Novo Nordisk itself: fewer heart-drug trials mean fewer potential future products or label expansions from that part of the pipeline. The company’s existing revenue base and profitability provide operating scale, but they do not replace the clinical optionality lost when programs are discontinued.
The main uncertainty is what drove the decisions and how material the two trials were to Novo Nordisk’s broader development strategy. The next useful evidence will be the company’s explanation of the programs, updates on remaining pipeline candidates and the next quarterly disclosure of operating performance.
Our read · Thu, Sep 17
Novo Nordisk (NVO) stopped two additional heart-drug trials, adding to setbacks in its development pipeline.
Why. The cancellations narrow Novo Nordisk’s future-product optionality and make the remaining pipeline more important to sustaining growth beyond the current portfolio. The company’s FY2025 revenue of $309.1B and 33.1% net margin provide scale, but those older annual figures do not resolve the value of the discontinued programs or the strength of the replacements.
Both cases
What could change this view: The read weakens if Novo Nordisk identifies the trials as non-core and shows that its remaining pipeline and current products can absorb the lost development optionality.
Who reported it · 1
Keep reading
More on NVO
Novo Nordisk's oral semaglutide now available in UK pharmacies as Wegovy alternativeLatest on the Wire
Trump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsIntesa Sanpaolo launches €34.5bn cash-and-share offer for Monte dei PaschiContinue on the Wire →Latest on the Wire
Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Yahoo Finance as Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trials
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →